Showing results (271-280 of 279) with videos related to
Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 279 results.
The Journal of Infectious Diseases|April 1, 1986
Serological characterization of HTLV-III infection in AIDS and related disordersJ E Groopman, F W Chen, J A Hope, et al.Internal Medicine Journal|November 6, 2014
Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of responseS Ghaly, S Costello, L Beswick, et al.Internal Medicine Journal|March 4, 2015
Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patientsS P Costello, S Ghaly, L Beswick, et al.The American Journal of Physiology|April 13, 1999
Validation of a novel luminal flow velocimeter with video fluoroscopy and manometry in the human esophagusJ M Andrews, H Nathan, C H Malbert, et al.Internal Medicine Journal|March 5, 2014
Perspectives of paediatric and adult gastroenterologists on transfer and transition care of adolescents with inflammatory bowel diseaseE K Wright, J Williams, J M Andrews, et al.Alimentary Pharmacology & Therapeutics|May 27, 2016
Review article: acute severe ulcerative colitis - evidence-based consensus statementsJ-H Chen, J M Andrews, V Kariyawasam, et al.Alimentary Pharmacology & Therapeutics|October 14, 2017
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseasesN Mitrev, N Vande Casteele, C H Seow, et al.Alimentary Pharmacology & Therapeutics|December 21, 2016
Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort studyJ D Doecke, F Hartnell, P Bampton, et al.Alimentary Pharmacology & Therapeutics|August 29, 2015
Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysisP De Cruz, M A Kamm, A L Hamilton, et al.Pageof 28